AKT1 and cancer: Mertk has been reported to activate multiple signaling pathways (JAK/STAT, MAPK, PI3K/AKT, EMT, and PD-1/PD-L1) to promote tumor cell migration, immune escape, and cancer stem cell (CSC) transformation, and act as bypass mechanisms to EGFR blockade (26).